Maja M. Janas

Alnylam Pharmaceuticals (United States) US

0000-0003-2110-539X

Publications

2,707

Citations

H-Index

i10-Index

1.0

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates

S. Agarwal, Elizabeth Taft, M. Gauthier, Justin Darcy, Kira Buckowing - Nucleic Acid Therapeutics, 2025

Cited by 0 Semantic Scholar

Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials. OA

E. Gane, Y. Lim, J. B. Kim, Vasant Jadhav, Ling Shen - Journal of Hepatology, 2023

Cited by 76 Semantic Scholar

Shorter Is Better: The α-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs. OA

S. Matsuda, Saikat Bala, Jen-Yu Liao, Dhrubajyoti Datta, Atsushi Mikami - Journal of the American Chemical Society, 2023

Cited by 27 Semantic Scholar

Rational optimization of siRNA to ensure strand bias in the interaction with the RNA-induced silencing complex.

Dhrubajyoti Datta, Christopher S. Theile, Kelly Wassarman, June Qin, T. Racie - Chemical Communications, 2023

Cited by 6 Semantic Scholar

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

Robin McDougall, D. Ramsden, Sagar Agarwal, S. Agarwal, Krishna C. Aluri - Unknown Venue, 2022

Cited by 0 Semantic Scholar

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization OA

M. Schlegel, Maja M. Janas, Yongfeng Jiang, J. Barry, Wendell P. Davis - Nucleic Acids Research, 2022

Cited by 69 Semantic Scholar

Research Topics

RNA Interference and Gene Delivery (17) MicroRNA in disease regulation (16) Advanced biosensing and bioanalysis techniques (15) RNA modifications and cancer (8) RNA Research and Splicing (7)

Affiliations

Broad Institute

US 2013 - 2009

Harvard University

US 2013 - 2008

Alnylam Pharmaceuticals (United States)

US 2025 - 2015

Dana-Farber Cancer Institute

US 2013 - 2009

Harvard Stem Cell Institute

US 2008 - 2008

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Maja M. Janas

Publication & Citation Trends

Publications

Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates

Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials. OA

Shorter Is Better: The α-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs. OA

Rational optimization of siRNA to ensure strand bias in the interaction with the RNA-induced silencing complex.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization OA

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back